Department of Pharmaceutical Sciences, Central University of Haryana, Haryana 123031, India.
Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia.
Curr Pharm Des. 2023;29(40):3254-3262. doi: 10.2174/1381612829666230712162540.
The prevalence of vaginal infection is increasing among women, especially at reproductive age. For proper eradication of infection, the effective concentration of a drug is required at the infection site. Therefore, local delivery is recommended to exert a direct therapeutic effect at the site action that causes a reduction in dose and side effects. The main focus of vaginal drug delivery is to enhance retention time and patient compliance. The high recurrence rate of vaginal infection due to the lack of effective treatment strategies opens the door for new therapeutic approaches. To combat these setbacks, intravaginal gene therapies have been investigated. High attention has been gained by vaginal gene therapy, especially for sexually transmitted infection treatment. Despite much research, no product is available in the market, although in vitro and preclinical data support the vaginal route as an effective route for gene administration. The main focus of this review is to discuss the recent advancement in miniaturized polymeric systems for intravaginal gene therapies to treat local infections. An overview of different barriers to vaginal delivery and challenges of vaginal infection treatment are also summarised.
阴道感染在女性中越来越普遍,尤其是在生育年龄。为了彻底消除感染,需要在感染部位达到有效的药物浓度。因此,建议局部给药,以便在引起剂量减少和副作用的部位发挥直接的治疗作用。阴道药物输送的主要重点是延长保留时间和提高患者的依从性。由于缺乏有效的治疗策略,阴道感染的高复发率为新的治疗方法打开了大门。为了应对这些挫折,人们研究了阴道内基因治疗。阴道基因治疗受到了高度关注,特别是用于治疗性传播感染。尽管进行了大量研究,但市场上仍没有产品,尽管体外和临床前数据支持阴道途径作为基因给药的有效途径。本篇综述的主要重点是讨论用于治疗局部感染的微型化聚合物系统在阴道内基因治疗方面的最新进展。还概述了阴道递药的不同障碍和阴道感染治疗的挑战。